Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA sequencing data of human prostate cancer cells treated with androgen

ABSTRACT: To analyse and understand the differentially expressed genes following treatment with synthetic androgen (R1881)

ORGANISM(S): Homo sapiens

PROVIDER: GSE128749 | GEO | 2019/06/24

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Expression data from androgen treated LNCaP cells

Project description:Androgens are required for the development of normal prostate, and they are also linked to the development of prostate cancer. We used microarrays to understand the role of androgen in an androgen dependent, androgen receptor (AR) positive human metastatic cell line, LNCaP. LNCaP cells were grown in RPMI medium and they were subjected to stay in phenol-red free, RPMI with charcoal stripped serum for 48h. Synthetic androgen R1881 was added and the cells were allowed to grow for 48h. Control cells were given with corresponding amount of ethanol as vehicle which is used for the solubilization of R1881. Cells were harvested and RNA was isolated for microarray analysis.

2009-12-29 | E-GEOD-17044 | biostudies-arrayexpress

Identification of direct androgen-target genes in the prostate cancer cell line LNCaP

Project description:Transcriptional profiling of the LNCaP cell line treated with R1881 synthetic androgen and/or cycloheximide.

2014-06-14 | GSE22372 | GEO

Long-term androgen withdrawal and treatment (R1881) of LNCaP-FGC prostate cancer cells

2013-10-22 | GSE51460 | GEO

Modulation of Androgen Receptor Signaling in Hormonal Therapy-Resistant Prostate Cancer Cell Lines

Project description:Prostate epithelial cells depend on androgens for survival and function. In early prostate cancer, besides survival, androgens also regulated tumor growth, which is exploited by androgen ablation/ blockade therapies in metastatic disease. The aim of the present study was to characterize the role of the androgen receptor pathway in prostate cancer progression and to identify potential disease markers. Microarray analysis was used to establish the androgen-regulated gene expression profile, upon stimulation with the synthetic androgen R1881 or the antiandrogen hydroxyflutamide, of the androgen-responsive PC346C cell line and its derivative castration-resistant sublines: PC346DCC (vestigial AR levels), PC346Flu1 (AR overexpression) and PC346Flu2 (T877A mutated AR) PC346C, PC346DCC, PC346Flu1 and PC346Flu2 were stimulated with 1 nM R1881, 1uM hydroxyflutamide or vehicle control, following a 4, 8 and 16h time-course. Each condition was performed in dye-swap, using biological duplicates. PC346DCC was only stimulated with R1881, not hydroxyflutamide.

2011-08-04 | E-GEOD-22914 | biostudies-arrayexpress

Long-term androgen withdrawal and treatment (R1881) of LNCaP-FGC prostate cancer cells

Project description:LNCaP cells were cultures in steroid depleted medium for 5 days before treatment with synthetic androgen (R1881, 10nM) for 16h. Transcriptomics analysis was performed to compare gene expression changes induced by androgen withdrawal or androgen treatment. Genome-wide transcriptomic analysis of LNCaP cells grown in steroid depleted medium, normal (steroid-containing) medium and R1881 treated cells was performed using the Agilent platform

2013-10-22 | E-GEOD-51460 | biostudies-arrayexpress

Genome-wide RNA-sequencing (RNA-seq) of benign and malignant prostate cell lines without and with androgen (R1881) stimulation.

Project description:RNA-seq data were obtained from hTERT immortalized human prostate transit amplifying EP156T cells (+/- 10 nM R1881 for 48 hrs), progeny tumorigenic EPT3-M1 cells recovered from mouse metastatic tumor (+/- 10 nM R1881 for 48 hrs) and the prostate cancer cell lines LNCaP (+/- 10 nM R1881 for 48 hrs), VCaP (+/- 1 nM R1881 for 24 hrs) and 22Rv1 (+/- 1 nM R1881 for 24 hrs) (obtained from the American Type Culture Collection). All cells were either stimulated or not stimulated with the synthetic androgen R1881 (1 or 10 nM for 24 or 48 hrs) prior to lysis (Qiagen miRNeasy minikit lysis buffer) and total RNA purification and DNase treatment.

2017-02-09 | GSE71797 | GEO

Androgen repsonsive microRNAs in LNCaP cell Lines

Project description:The goals of this study were to evaluate changes in microRNA expression following androgen treatment. Four treatment groups were studied: untreated and those treated with 0.1, 1.0, and 10.0 nM of synthetic androgen (R1881). Data is relative to the untreated sample.

2010-06-20 | E-GEOD-16212 | biostudies-arrayexpress

Androgen repsonsive microRNAs in LAPC-4 cell lines

2010-06-20 | E-GEOD-16213 | biostudies-arrayexpress

Identification of direct androgen-target genes in the prostate cancer cell line LNCaP

Project description:Transcriptional profiling of the LNCaP cell line treated with R1881 synthetic androgen and/or cycloheximide. LNCaP cells were stimulated with R1881 alone, with cycloheximide alone, or with R1881 in the presence of cycloheximide for 24h and compared to control untreated cells. Two independent cell culture experiments for each treatment condition were performed for microarray analysis. Each experiment was repeated with a switch in fluorescent Cy3/Cy5 labels to account for dye effects to produce four data points per hybridization spot.

2014-06-14 | E-GEOD-22372 | biostudies-arrayexpress

Chromatin immunoprecipitation of human LNCaP cells treated with synthetic androgen R1881 or ethanol (vehicle) using androgen receptor antibody

Project description:LNCaP cells were grown in charcoal stripped media for 48hrs and then treated for 1hr with the synthetic androgen R1881 or ethanol (vehicle). Cell extracts from both treatment conditions were then subjected to chromatin-immunoprecipitation using an anti-androgen receptor antibody, before labeling and hybridisation to a microarray containing 24,000 gene promoter regions.

2007-08-17 | E-TABM-233 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data